文献速递血脂与心血管预防

重新审视绝经激素治疗:适用人群、方案、时机与疗程

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
PubMed 文献 · Circulation · 2023-02-13

本文由美国心脏病学会女性心血管病委员会牵头,联合妇产科、内科和内分泌专家,综述绝经激素治疗与心血管风险的关系。文章基于既往一级和二级预防试验中雌孕激素联合治疗增加心血管风险的发现,结合用药时机、年龄、绝经时间和给药途径,为有症状且伴心血管风险的女性提供激素治疗选择指导。

要点

  • 四个主要医学会推荐绝经激素治疗用于缓解困扰性绝经症状。
  • 激素治疗的心血管风险与开始时机、年龄和绝经时间相关。
  • 需个体化选择患者和激素制剂,尤其关注有心血管风险的 symptomatic 女性。

核心结论

  • 绝经激素治疗的心血管风险与用药时机、年龄、绝经时间和给药途径相关,需个体化评估。

研究设计与样本

  • 综述由美国心脏病学会女性心血管病委员会牵头,联合妇产科、女性健康内科和内分泌专家共同完成。

主要发现

  • 既往一级和二级预防试验报告雌孕激素联合治疗增加心血管风险,导致激素治疗使用显著下降。
  • 过去20年对激素治疗时机、给药途径与心血管风险的关系有了更多认识。

关键数值与推荐

  • 四个主要医学会推荐激素治疗用于治疗有困扰性绝经症状的绝经女性。

临床怎么用

  • 为有绝经症状的女性选择激素治疗时,应评估年龄、绝经时间、给药途径和心血管风险。
  • 尤其需关注有心血管疾病风险的症状性女性,个体化选择激素制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Cho L, Kaunitz AM, Faubion SS, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023. PMID: 36780393. doi:10.1161/CIRCULATIONAHA.122.061559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。